Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vividion Therapeutics, Inc.

https://vividion.com/

Latest From Vividion Therapeutics, Inc.

Women’s Health Still Key to Bayer Despite Early Research Shift

The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.

Women's Health Strategy

No Slowdown From Bayer On Business Development Front

“We're looking at opportunities almost on a weekly basis,” Bayer’s pharma chief Stefan Oelrich told Scrip as the German major posted a solid set of financials for the fourth quarter.

Sales & Earnings Business Strategies

Dealmaking Quarterly Statistics, Q4 2022

During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.

Deals Market Intelligence

Five Challenges Bill Anderson Faces At Bayer

Six weeks after leaving Roche, Bill Anderson is taking the helm at Bayer in one of the most intriguing appointments in the sector for some time.

Leadership Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register